Cuker A - Search Results

1

Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia.

Cuker A, Chiang EY, Cines DB. Cuker A, et al. Curr Drug Saf. 2010 Apr;5(2):171-81. doi: 10.2174/157488610790936196. Curr Drug Saf. 2010. PMID: 19534637 Review.

2

Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.

Cuker A, Ptashkin B, Konkle BA, Pipe SW, Whinna HC, Zheng XL, Cines DB, Pollak ES. Cuker A, et al. J Thromb Haemost. 2009 Jan;7(1):80-6. doi: 10.1111/j.1538-7836.2008.03224.x. Epub 2008 Nov 11. J Thromb Haemost. 2009. PMID: 19017257 Free article.

3

The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.

Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB. Cuker A, et al. J Thromb Haemost. 2010 Dec;8(12):2642-50. doi: 10.1111/j.1538-7836.2010.04059.x. J Thromb Haemost. 2010. PMID: 20854372 Free article.

4

Immune thrombocytopenia.

Cuker A, Cines DB. Cuker A, et al. Hematology Am Soc Hematol Educ Program. 2010;2010:377-84. doi: 10.1182/asheducation-2010.1.377. Hematology Am Soc Hematol Educ Program. 2010. PMID: 21239822 Review.

5

Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?

Cuker A, Cines DB. Cuker A, et al. Hematology Am Soc Hematol Educ Program. 2010;2010:385-6. doi: 10.1182/asheducation-2010.1.385. Hematology Am Soc Hematol Educ Program. 2010. PMID: 21239823 Review.

6

Heparin-induced thrombocytopenia: present and future.

Cuker A. Cuker A. J Thromb Thrombolysis. 2011 Apr;31(3):353-66. doi: 10.1007/s11239-011-0569-6. J Thromb Thrombolysis. 2011. PMID: 21327506 Review.

7

Recent advances in heparin-induced thrombocytopenia.

Cuker A. Cuker A. Curr Opin Hematol. 2011 Sep;18(5):315-22. doi: 10.1097/MOH.0b013e3283497ef2. Curr Opin Hematol. 2011. PMID: 21730833 Review.

8

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH. Cuker A, et al. Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29. Blood. 2011. PMID: 21960587 Free article. Clinical Trial.

9

False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A(IID) von Willebrand disease.

Ahmad S, Ptashkin B, DiGiovanni C, Cines DB, Konkle BA, Cuker A. Ahmad S, et al. Among authors: cuker a. Thromb Haemost. 2011 Dec;106(6):1224-5. doi: 10.1160/TH11-07-0484. Epub 2011 Oct 6. Thromb Haemost. 2011. PMID: 21979291 No abstract available.

10

How I treat heparin-induced thrombocytopenia.

Cuker A, Cines DB. Cuker A, et al. Blood. 2012 Mar 8;119(10):2209-18. doi: 10.1182/blood-2011-11-376293. Epub 2012 Jan 13. Blood. 2012. PMID: 22246036 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters